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There is a burgeoning literature in health economic evaluation, with this form of 
analysis becoming increasingly influential at the health policy making level in a 
number of countries. However, a search of the literature reveals that in Japan, the 
world’s second largest health care market, very little health economic evaluation has 
been undertaken. The main reason for the lack of interest in economic evaluation is 
that the fee-for-service and strict price regulation that characterises the system of 
health care financing in Japan is not conducive to this form of analysis. Moreover, the 
government and many researchers are satisfied that the current organisation of health 
care has given long life and low infant mortality at low cost. Even if it is accepted that 
low health care costs and good health prevail in Japan, slower economic growth rates, 
an ageing population and the development of new medical technologies will place 
increasing pressure on health care resources and will necessitate a more rational use of 
these resources. Good economic evaluation, by weighing benefits against costs, has an 
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  1   Introduction 
 
One aspect of health technology assessment that is becoming increasingly influential 
at the health policy making level in a number of countries is health economic 
evaluation (e.g., Ministry of Health, 1994; Commonwealth of Australia, 1995; 
Norwegian Medicines Control Agency, 1999; Sickness Funds Council, 1999; NICE, 
2001). Health economic evaluation, by weighing benefits against costs, can help 
decision makers to allocate scarce health care resources more efficiently. By 
informing the decision maker of the most efficient ways to use health care resources, 
health economic evaluation is potentially more useful than aspects of health 
technology assessment that merely assess the effectiveness of health care 
interventions, which only offers information on whether an intervention is clinically 
beneficial without any reference to cost. 
 
The purpose of this paper is to review the state of health economic evaluation in 
Japan, the world’s second largest health care market, with a view to uncovering 
whether Japan can offer any lessons with respect to this highly important aspect of 
health technology assessment. 
 
 
Review of Japanese economic evaluation 
 
From a search of the literature, we can obtain some idea of the state of health 
economic evaluation in Japan. A search of the Health Economics Evaluations 
Database (HEED) was undertaken. This search included cost, cost-consequences and 
cost of illness analyses, in addition to the more accepted forms of economic 
evaluation (i.e. cost-minimisation, cost-effectiveness, cost-utility and cost-benefit 
analyses). Before going further, two caveats concerning the use of this database 
should be noted. 
 
First, the database provides comprehensive coverage of only the post-1992 published 
literature. However, other studies, some with a particular emphasis on 
pharmacoeconomic analyses, have undertaken searches that extend to the pre-1992 
literature, and have found very few studies directly applicable to Japan (Moriga et al., 
1995; Ikeda et al., 1996a; Hisashige, 1997; Hamashima et al., 1998; Kishimoto, 
1999).  
 
Second, HEED does not adequately cover the Japanese language literature. The 
articles detected as relevant from the search of HEED were all written in English. 
However, the few Japanese researchers active in economic evaluation aspire to 
publish their work in English language journals, and there are currently no established 
Japanese journals to which economic evaluations can be submitted (Ikegami, 1999). 
Whilst the search criteria used in this article does not provide an exhaustive search of 
post-1992 Japanese economic evaluation, it is assumed that the search detected a 
sufficient sample of published economic evaluations to enable some conclusions to be 
made concerning the state of economic evaluation in Japan.  
 
The search was narrowed to Japanese authors undertaking original applied economic 
evaluation in Japan. Twenty-five articles were detected. By international comparison, 
this number is low. For example, using identical search criteria applicable to each 
  2   country, the number of applied economic evaluations included on HEED for the 
remaining G7 countries of Canada, France, Germany, Italy, the UK and the USA 
measured 319, 106, 83, 109, 630 and 2,610, respectively. Moreover, with respect to 
the number of published economic evaluations, many countries with relatively small 
health care sectors appear to be more active in the field of economic evaluation than 
Japan. For example, 150, 117 and 45 applied studies were detected for Sweden, the 
Netherlands and Finland, respectively. If it is assumed that the number of published 
applied studies gives some indication of the development of this discipline, it is 
perhaps notable that Japan appears to be grouped with countries such as Belgium (24 
studies) and Thailand (16 studies) rather than with the larger industrialised nations.  
 
A technical appendix of the studies detected from the search of HEED is available 
from the author on request. To summarise the results of the search, there has been a 
small, steady number of economic evaluations published by Japanese researchers over 
recent years, but there is no sign of an increasing trend in the number of studies 
published over time. Most of the studies tend to adopt a cost-consequence design. No 
author(s) dominates the applied economic evaluation literature, and most received 
their formal training in the clinical sciences. In terms of medical intervention, 
screening and diagnostics are the main foci of interest, and cancer is the most 
frequently analysed disease. The biggest single source of funding for these economic 
evaluations was the Japanese government. With reference to these results, I shall now 




The disincentives for undertaking economic evaluation 
 
The main disincentives for undertaking economic evaluation in Japan arise from the 
way in which the health care financing system is organised. The financing structure is 
described in more detail elsewhere (e.g., Ikegami, 1988; 1992; Ikegami et al., 1994; 
Ikegami and Campbell, 1995; 1996; Oliver et al., 1997), but its salient features are 
that it is a fee-for-service system based on a tightly controlled fee schedule, where 
across the board reductions in fees - irrespective of an intervention’s effectiveness or 
value for money - are regularly imposed by the government. The ways in which the 
system of health care financing, together with other factors, serve to restrict the 
incentives for the government, purchasers, providers, manufacturers and universities 
to commission and/or undertake economic evaluation, will now be detailed. 
 
 
Government and purchasers  
 
Several research groups have been organised by the government and academia over 
recent years for the partial purpose of considering economic evaluation (Hisashige, 
1997). Moreover, there have been calls from the government about the need to 
establish economic evaluation in the field of health care, particularly for 
pharmaceuticals (Hisashige et al., 1998). However, the extent to which these calls will 
be heeded, and the degree of commitment that the government has in developing an 
environment that gives the appropriate incentives for high quality economic 
evaluation, is not clear.  
 
  3   Through the tight control of the fee schedule, the financial strain of reimbursing new 
medical procedures is suppressed. Universal insurance coverage entitles everybody to 
the same health care treatments, theoretically facilitating access to the latest, and, 
assumed, highest quality interventions. The low cost and perceived equity of access 
has removed the urgency within the government and insurers to actively pursue 
evidence of cost-effectiveness for the purpose of prioritising health care. Also, since 
insurance enrolment is based on employment or residence and not choice, there is no 
competition between insurance plans, and an extensive system of insurer subsidisation 
and cross-subsidisation by the government has weakened the incentives for the 
insurers to weigh the outcomes of medical interventions against costs. Unfortunately, 
it is likely that the strict control of prices without reference to incremental clinical 
efficacy, effectiveness and/or value for money has a distorting and detrimental 





The fee-for-service nature of the system allows the health care providers to be 
reimbursed for their activity without direct reference to a budget, and removes the 
incentive for them to balance outcomes against costs. In some areas of health care the 
fee-for-service system and the suppression of reimbursement prices motivates the 
providers to increase their volume of service, possibly to a level where the marginal 
benefit falls below zero. This is particularly evident in pharmaceuticals and diagnostic 
procedures (Hisashige, 1994; Oliver et al., 1999).  
 
The decision to introduce high-tech health care is often based on the perception that 
the latest or seemingly more sophisticated developments in medical technology are 
necessarily highly effective. This perception is particularly pertinent in the larger 
hospitals, the administrators of which invest in high-tech health care in order to 
maintain prestige, which is then used to attract both physicians and patients (Ikegami, 
1992). The view that ‘new is best’ may be culturally ingrained. Therefore, the 
removal of the perverse financial incentives offered by the current system may not 
immediately or entirely discourage the hospital administrators from investing in and 
administering the latest interventions before incremental clinical efficacy, let alone 
cost-effectiveness, is established. Nevertheless, separating revenue generation from 
health care provision may well introduce the incentives for the providers to assess 





The lack of consideration of an intervention’s quality (in terms of its degree of 
efficacy, effectiveness and/or cost-effectiveness) in the fee schedule weakens the 
incentives for the manufacturers of health care interventions to demonstrate the 
usefulness of their products. This is particularly evident in the pharmaceutical 
industry. Pharmaceutical reimbursement prices are regularly reduced irrespective of 
quality. This gives the incentive for the manufacturers to continually introduce new 
drugs, which are generally priced slightly higher than existing comparable therapies 
(Ikegami et al., 1994). Also, physicians are eager to prescribe new drugs for reasons 
of profit (due to relatively high margins between the reimbursement and market 
  4   prices) and prestige. In 1992, the MHW issued guidelines stating that innovative 
drugs would be priced at a premium level, though between May 1992 and November 
1995, only 1 of the 183 new drugs introduced onto the market was priced as 
‘innovative’ (Ikeda et al., 1996b). Furthermore, the pricing decisions made during 
negotiations between the Ministry of Health and Welfare (MHW) and the Japan 
Medical Association (JMA) are closed, which makes it difficult for the manufacturers 
to determine exactly what is required for their products to be classified as innovative.  
 
Most Japanese pharmaceutical manufacturers generally forgo the risk and expense of 
attempting to develop innovative products and restrict themselves to producing ‘me-
too’ drugs. These products differ very little in their chemical compound from existing 
drugs and offer only limited improvements in therapeutic benefit. However, they are 
relatively inexpensive to develop, can be marketed as ‘major innovations’ and, as 
noted above, are priced above existing medicines in the same therapeutic category. 
Japanese pharmaceutical companies are sure that their me-too products will enter the 
market at a relatively high price, but are unsure of what they have to prove to attain a 
premium price. They are certain that whatever they produce, the reimbursement price 
will be subjected to regular reductions. In this environment there is little incentive for 
the manufacturers to undertake economic evaluation in order to prove a product’s 





Of the 25 articles detected from the search of HEED, 21 gave author contact details. 
Sixteen corresponding authors were based in university medical departments, 2 in 
cancer institutes, 1 in a national hospital, 1 in a clinic and 1 in an American hospital. 
The large majority of the authors of these studies are physicians. It appears that those 
in Japan who undertake studies of health care interventions that contain some 
consideration of costs are predominantly university hospital-based physicians.  
 
A possible reason why those with medical backgrounds tend to dominate health 
economic evaluation is because the medical profession in Japan is highly paternalistic, 
and medical doctors are resistant to what they may consider to be outside influences 
over their decisions (Feldman et al., 1994). That physicians undertake the few 
economic evaluations that are published has important implications. First, the extent 
to which many physicians fully understand the principles of good economic 
evaluation is unclear. Very often, studies tend to include cost data almost as an 
afterthought rather than as an integral part of the analysis. This is associated with the 
physicians’ main concern with demonstrating the clinical consequences of medical 
interventions. Where physicians do venture to focus upon more formal economic 
analysis, it is often the case that they lack the training to incorporate the appropriate 
requirements necessary for good quality evaluations. 
 
Another implication of university-based physicians predominantly undertaking 
economic evaluation is that existing analyses may reflect their own medical research 
interests rather than any fundamental drive to estimate the most rational use of 
resources across the whole health care system. These research interests are likely to be 
partly determined by the forms of health care that are readily available. For example, 
mass screening for stomach, cervix, endometrium, lung, breast and colon/rectum 
  5   cancers is available in Japan at government subsidised rates or at no charge for the 
employees of most companies (Oshima, 1994). Screening for a host of other 
conditions, such as paediatric renal and heart diseases, are also widely available 
(Hisashige, 1997). Screening practices and the installation of diagnostic equipment 
may be relatively common because of the revenue that can be derived from 
voluminous diagnostic testing, and/or because the hospital administrators feel that 
investing in the latest diagnostic equipment is effective in attracting both patients and 
doctors. Alternatively, the popularity of screening and diagnostics could be based on a 
cultural preference for non-invasive techniques (Ikegami, 1988; Hisashige, 1997). The 
above factors may explain why screening, diagnostic procedures and cancer appear to 
be the foci of interest with respect to economic evaluation.  
 
Overall, the incentives for the government, purchasers, providers, manufacturers and 
universities to involve themselves in economic evaluation are currently weak. But is 
more economic evaluation really warranted?  
 
 
The case for more economic evaluation  
 
It is well documented that the Japanese spend a relatively low proportion of their 
gross domestic product (GDP) on health care (e.g., Ikegami and Campbell, 1995; 
Ikegami, 1997). It is also well documented that despite this seemingly well controlled 
health care expenditure, the macro health indicators of life expectancy and infant 
mortality are among the best in the world (e.g., Ikegami and Campbell, 1995; Oliver 
et al., 1997). Many researchers have drawn attention to these facts, which has 
somewhat deflated the pressure for reform that would introduce incentives for the 
various parties to focus on economic evaluation.  
 
 
Health care spending as a percentage of GDP 
 
Though health care expenditure as a percentage of GDP is low by international 
comparison, Japan’s economic performance over recent years has been poor. Hence, 
the growth in GDP has been slow and the percentage of GDP spent on health care 
might be expected to rise. Whether Japan’s economy will ever fully recover to the 
position the country had become accustomed to before the 1990s is an open question, 
but a relatively low proportion of GDP spent on health care should not be taken for 
granted, and the lower levels of economic growth necessitate a more careful 
utilisation of health care resources.  
 
Poor economic performance is not the only factor that is contributing to the increasing 
pressure for a more rational use of health care resources. Japan has a population that is 
ageing more rapidly than those of most other countries. This will possibly place an 
increasing strain on the health care budget due to the possible higher prevalence of 
age-related diseases (Hisashige, 1993; Oliver et al., 1997; Hisashige et al., 1998). 
Also, the higher ratio of retired to people of working age within the population 
diminishes the insurance premium and tax base.  
 
Finally, the development of new medical technology continues at an ever increasing 
rate (Hisashige, 1997). This will place more financial strain on certain providers, 
  6   specifically those where the investment in the latest technology is deemed necessary 
due to the pervading attitude that ‘new is best’.  
 
 
Current macro indicators 
 
Many researchers frequently mention that Japan has very good life expectancy and 
infant mortality indicators and that, therefore, the Japanese are a relatively healthy 
population. The first point to note regarding this, as acknowledged by many of the 
researchers themselves, is that the health care system is not the sole, or even the main, 
contributor to these good macro indicators. It is probable that many other factors 
influence life expectancy and infant mortality rates, including income growth, income 
distribution, diet, housing etc. (Hisashige, 1992; Oliver et al., 1997). Thus, the good 
macro indicators are not an adequate reason to be complacent with respect to the 
benefits accruing from the current organisation of the health care system. There is also 
the question regarding the extent to which the macro indicators accurately reflect the 
health status of the population. It may well be that the members of a society, on 
average, live a long time, but their quality of life is at least as important. Moreover, it 
is worth noting that favourable international comparisons should not give grounds for 
complacency, as there is always likely to be room for improvements within any 
country.    
 
  
Introducing incentives for economic evaluation 
 
The Japanese government has been successful in containing health care costs (Oliver 
et al., 1999). However, cost-containment alone is not a measure of a successful health 
care system, and an environment ought to be created where there are incentives to 
measure the value for money of new and existing health care interventions. The 
decision maker will then be in a better position to prioritise health care interventions. 
How might this environment be created?  
 
 
Introducing provider budgets 
 
The most important reforms necessary to encourage economic evaluation are to 
change the fee-for-service nature of reimbursement and remove the regular across-
the-board reductions in the fee schedule. A system needs to be introduced that takes 
away the revenue-based incentives for the providers to undertake and administer 
unnecessary procedures and services. The widespread introduction of health care 
provider budgets could provide incentives for economic evaluation to be undertaken, 
and would also continue to facilitate health care cost control. Concurrently, the price 
reduction policy should be replaced with a price recommendation system that accords 
with each health care intervention’s value for money. 
 
In a budget-based system, the insurance funds would negotiate contracts with clinics 
and hospitals to provide appropriate care for their insured populations over a fixed 
period. Currently in Japan, there are hundreds of insurance funds, and therefore this 
initiative may require many of the funds to merge. Also, contracting with specific 
providers may initially prove unpopular with many insurance fund enrolees since 
  7   people currently enjoy the freedom to attend any hospital they wish. However, a 
budget-based system with purchaser-provider contracting may give the government 
and the insurers the incentive to commission economic evaluation on new and 
existing interventions and disseminate the results to the health care providers in an 
attempt to encourage the use of the most beneficial care for each unit of health care 
cost. The providers would also have an incentive to commission economic evaluation 
in order to help provide the best possible care inside their budget constraint. This may 
place them in a strong negotiating position regarding future health care contracts by, 
for example, helping them to maximise population health status gains, subject to 
equity considerations.  
 
The manufacturers of health care interventions would be faced with more appropriate 
incentives to commission and undertake economic evaluation precisely because they 
would want to demonstrate that their products represent the best value for money. 
This could be reinforced if the government demanded the submission of good 
economic evaluation to help them in their pricing recommendations. Moreover, the 
method by which the government considers the results of economic evaluation ought 
to be overt. This may pose a particular problem as the confidential aspect of decision 
making is embedded in Japanese tradition. However, attempts to persuade the MHW 
and the JMA to publicly disclose the information that they draw upon during their 
negotiations are necessary in order to enable the manufacturers to scrutinise and, if 
necessary, appeal against the government’s decisions. If the government employs 
assessors with expertise in economic evaluation the health care manufacturers may 
have more confidence that their products are being subjected to price 
recommendations that reflect value for money, and would thus be given the incentive 
to produce high quality, internationally competitive products. 
 
 
Establishing the necessary expertise in economic evaluation 
 
Although changes to the structure of health care financing are necessary to remove the 
disincentives to commission and undertake economic evaluation, there are currently 
an insufficient number of experts able to undertake good economic evaluation in 
Japan. The government should invest in the training of a large number of experts who 
would remain independent of government and/or industry influence. Maintaining the 
independence of the experts will help ensure that the influence of those with a vested 
interest in the results of the analyses is kept to a minimum, and that each interested 
party is as confident as possible in the validity of the results. Although the 
government, insurers, providers and manufacturers may require experts to undertake 
and assess economic evaluation, the majority of the research should be commissioned 
from and undertaken within an independent academic environment. It is advisable that 
specific centres of excellence be established within the universities. 
 
 
Lessons from Japan?  
 
As the countries of the European Union form closer economic and political ties, it is 
becoming increasingly important to assess which health care systems ‘work’ (and why 
they work). However, we ought to guard against constructing an isolationist European 
Union point of view. Assessing the health care systems of non-European Union 
  8   countries is also important, not just with the view of ascertaining what we can learn 
from them, but also with a view to offering advice on what they can learn from us. 
Recent world events have served to underline the importance of maintaining a global 
perspective with respect to many aspects of policy development.  
 
In terms of developing health care systems that facilitate both investment in health 
economic evaluation and the incentives to act upon their consequent 
recommendations, the countries of the European Union, or indeed anywhere else, 
have very little to learn from Japan. In fact, I have argued that a budget-based system 





In many countries, economic evaluation is an increasingly influential aspect of health 
technology assessment, but in Japan relatively little health economic evaluation has 
been undertaken. The main reason is that the current system of health care financing 
does not provide the appropriate incentives to stimulate a powerful interest in this type 
of research. Many Japanese are nevertheless satisfied that good health care indicators 
are being achieved at low cost. However, due to slower economic growth, a rapidly 
ageing population and the increasing development of new medical technologies, 
health care resources are likely to be subjected to ever increasing pressures. A more 
rational use of health care resources to maintain and improve the health of the 
Japanese people is warranted. Concerning these considerations, economic evaluation, 
by weighing the benefits of medical interventions against their costs, has an important 
role to play.   
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